logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models

delete2025-08-25
delete0
delete
OA
AI
K
Ksenija Slavic Obradovic
F
Florian Ebner
A
Artem V. Artemov
M
Martina Miotto
P
Paula-Elena Traexler
R
Robin Jacob
H
Ha Pham Thi Thanh
R
Regina Ruzicka
A
Andreas Wernitznig
I
Ines Baumann
D
Daniel Gerlach
S
Salvatore Siena
M
Mary Y. Murphy
R
Reniqua House
U
Ulrich Reiser
V
Valeria Santoro
J
Johannes Popow
S
Sebastian Carotta
A
Anke Baum
J
Jesse Lipp
A
Alberto Bardelli
U
Ulrike Tontsch-Grunt
M
Mariangela Russo *
M
Martin Aichinger *
DOI：10.1016/j.xcrm.2025.102313delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
• BETi+SMACm inhibits cancer cell proliferation resulting in enhanced in vivo efficacy • Combination therapy modulates the tumor microenvironment and enhances anti-tumor immunity • CITE-seq in syngeneic PDAC model provides insight into impact on anti-tumor immunity
Keywords:
SMAC mimetic
cIAP
BET inhibition
cell death
tumor microenvironment
combination therapy
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Cell Reports Medicine cover
Cell Reports Medicine
IF:
10.6
Papers:
2.2K
Citations:
8.9K

Organization

B
boehringer ingelheim pharmaceuticals, inc
Scholars:
18
Papers: 9
Citations: 0
U
University of Torino
Scholars:
922
Papers: 332
Citations: 0
U
Università degli Studi di Milano
Scholars:
969
Papers: 405
Citations: 0
researcher View more organizations